PHVS
Pharvaris N.V.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
No implied move.
Next report
Last report
—
Largest filed tie
—
13F top-10 QoQ
Top fund weight
—
Pharvaris N.V.
Expected move
No implied move.
Next report
Last report
—
Largest filed tie
—
13F top-10 QoQ
Top fund weight
—
No changes.
No changes.
No trades yet today.
No trades yet today.
| Manager | Value | % base | |
|---|---|---|---|
| FMR | $227.0M | 10.16% | +4.47% |
| General Atlantic | $226.5M | 10.14% | −18.43% |
| Foresite Capital Management IV | $165.2M | 7.40% | 0.00% |
| venBio Partners | $160.6M | 7.19% | +0.09% |
| Viking Global Investors | $126.3M | 5.65% | 0.00% |
| Manager | Value | % base | |
|---|---|---|---|
| FMR | $227.0M | 10.16% | +4.47% |
| General Atlantic | $226.5M | 10.14% | −18.43% |
| Foresite Capital Management IV | $165.2M | 7.40% | 0.00% |
| venBio Partners | $160.6M | 7.19% | +0.09% |
| Viking Global Investors | $126.3M | 5.65% | 0.00% |
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for Pharvaris N.V..
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for Pharvaris N.V..
Annual filing, covered
20-F parsed · Apr 2 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
20-F parsed · Apr 2 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
Pharvaris N.V.
34.85
pre 34.78 0.00%
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.
—
—